| Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial A Tutt, H Tovey, MCU Cheang, S Kernaghan, L Kilburn, P Gazinska, ... Nature medicine 24 (5), 628-637, 2018 | 838 | 2018 |
| Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study L Monin, AG Laing, M Muñoz-Ruiz, DR McKenzie, IDM Del Barrio, ... The Lancet Oncology 22 (6), 765-778, 2021 | 606 | 2021 |
| Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally … D Miles, J Gligorov, F André, D Cameron, A Schneeweiss, C Barrios, B Xu, ... Annals of Oncology 32 (8), 994-1004, 2021 | 469 | 2021 |
| The development and clinical use of trastuzumab (Herceptin). M Harries, I Smith Endocrine-related cancer 9 (2), 75-85, 2002 | 312 | 2002 |
| 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial HM Earl, L Hiller, AL Vallier, S Loi, K McAdam, L Hughes-Davies, ... The Lancet 393 (10191), 2599-2612, 2019 | 294 | 2019 |
| Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial M Maio, K Lewis, L Demidov, M Mandalà, I Bondarenko, PA Ascierto, ... The Lancet Oncology 19 (4), 510-520, 2018 | 230 | 2018 |
| IgG4 subclass antibodies impair antitumor immunity in melanoma P Karagiannis, AE Gilbert, DH Josephs, N Ali, T Dodev, L Saul, I Correa, ... The Journal of clinical investigation 123 (4), 1457-1474, 2013 | 226 | 2013 |
| Abstract S3-01: the TNT trial: a randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple … A Tutt, P Ellis, L Kilburn, C Gilett, S Pinder, J Abraham, S Barrett, ... Cancer Research 75 (9_Supplement), S3-01-S3-01, 2015 | 223 | 2015 |
| Part I: Chemotherapy for epithelial ovarian cancer–treatment at first diagnosis M Harries, M Gore The lancet oncology 3 (9), 529-536, 2002 | 218 | 2002 |
| Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma KA Lee, AM Thomas, LA Bolte, JR Björk, LK de Ruijter, F Armanini, ... Nature Medicine 28 (3), 535-544, 2022 | 215 | 2022 |
| Part II: Chemotherapy for epithelial ovarian cancer-treatment of rcurrent disease M Harries, M Gore The lancet oncology 3 (9), 537-545, 2002 | 205 | 2002 |
| Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early … HM Earl, AL Vallier, L Hiller, N Fenwick, J Young, M Iddawela, J Abraham, ... The lancet oncology 15 (2), 201-212, 2014 | 150 | 2014 |
| Nanoparticle albumin-bound paclitaxel for metastatic breast cancer M Harries, P Ellis, P Harper Journal of clinical oncology 23 (31), 7768-7771, 2005 | 146 | 2005 |
| Changes in primary breast cancer heterogeneity may augment midtreatment MR imaging assessment of response to neoadjuvant chemotherapy J Parikh, M Selmi, G Charles-Edwards, J Glendenning, B Ganeshan, ... Radiology 272 (1), 100-112, 2014 | 139 | 2014 |
| Internal ribosome entry site regulates translation of Kaposi's sarcoma-associated herpesvirus FLICE inhibitory protein W Low, M Harries, H Ye, MQ Du, C Boshoff, M Collins Journal of virology 75 (6), 2938-2945, 2001 | 123 | 2001 |
| Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study PG Corrie, A Marshall, JA Dunn, MR Middleton, PD Nathan, M Gore, ... The Lancet Oncology 15 (6), 620-630, 2014 | 119 | 2014 |
| Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma K Palmer, J Moore, M Everard, JD Harris, S Rodgers, RC Rees, ... Human gene therapy 10 (8), 1261-1268, 1999 | 106 | 1999 |
| Age at diagnosis and distant metastasis in breast cancer–a surprising inverse relationship A Purushotham, E Shamil, M Cariati, O Agbaje, A Muhidin, C Gillett, ... European journal of cancer 50 (10), 1697-1705, 2014 | 105 | 2014 |
| Incidence of bone metastases and survival after a diagnosis of bone metastases in breast cancer patients M Harries, A Taylor, L Holmberg, O Agbaje, H Garmo, S Kabilan, ... Cancer epidemiology 38 (4), 427-434, 2014 | 98 | 2014 |
| A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma SM Rudman, MB Jameson, MJ McKeage, P Savage, DI Jodrell, M Harries, ... Clinical Cancer Research 17 (7), 1998-2005, 2011 | 97 | 2011 |
